Evogene (XTAE:EVGN) Cash, Cash Equivalents, Marketable Securities : ₪116.00 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Evogene Cash, Cash Equivalents, Marketable Securities?

Evogene's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 (₪126.49 Mil) to Sep. 2023 (₪139.01 Mil) but then stayed the same from Sep. 2023 (₪139.01 Mil) to Dec. 2023 (₪116.00 Mil).

Evogene's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (₪201.15 Mil) to Dec. 2022 (₪132.02 Mil) and declined from Dec. 2022 (₪132.02 Mil) to Dec. 2023 (₪116.00 Mil).

Evogene Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Evogene's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Cash, Cash Equivalents, Marketable Securities Chart

Evogene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

175.04

180.10

201.15

132.02

116.00

Evogene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															132.02	107.53	126.49	139.01	116.00

Evogene Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Evogene (XTAE:EVGN) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Evogene Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Evogene's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Evogene (XTAE:EVGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

EVGN:USA

Address

13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002

Website

https://www.evogene.com

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.